This report evaluates whether full-text clinical studies and clinical practice guidelines and position statements support the use of delandistrogene moxeparvovec-rokl (Elevidys; Sarepta Therapeutics Inc.) for treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 to 8 years.